To study the clinical value of different doses febuxostat in treating chronic kidney disease (CKD) patients with hyperuricemia (HUA).

90 CKD patients with HUA were enrolled and randomly divided into three groups with 30 patients each. All the three groups received basic treatment. And group A were treated with allopurinol 300 mg/d, group B treated with febuxostat 40 mg/d, while group C treated with febuxostat 80 mg/d. The course of treatment was 6 months. The therapeutic effects and adverse reactions among the three groups were compared with Chi-square test, and the renal function and serum uric acid (SUA) level before and after treatment were compared with paired t test.

There were significant differences in therapeutic effects among the three groups (χ²=7.917, P=0.019), and the therapeutic effects of groups B and C were better than that of group A (χ²=4.356, 5.963; P=0.037, 0.015, respectively). After treatment, the levels of SUA in group B and group C were both significantly lower than that in group A (t=4.018, t=5.437; P<0.05), and the incidence of adverse reactions in group B was lower than in group A or group C without statistical significance.

The therapeutic effect of febuxostat for CKD with hyperuricemia was better than that of allopurinol. Small doses of febuxostat was with higher level of safety than the larger doses.